Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 EBITDA Margin % is 25.77% as of Mar. 2026, which is 19% below its 10-year median of 31.77. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Jacobson Pharma ranks better than 79.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Jacobson Pharma's EBITDA for the
six
months ended in Mar. 2026 was HK$207 Mil. Jacobson Pharma's Revenue for the
six
months ended in Mar. 2026 was HK$803 Mil. Therefore, Jacobson Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 25.77%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jacobson Pharma EBITDA Margin % Related Terms
Jacobson Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a EBITDA Margin % of 25.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jacobson Pharma and its competitors. This is 19% below median its historical median of 31.77. Over the past decade, Jacobson Pharma's EBITDA Margin % has ranged from 25.06 to 39.15. According to the industry distribution chart, Jacobson Pharma ranks #194 out of 959 companies in the Drug Manufacturers industry, placing it in the top 20.2%.
Is Jacobson Pharma's EBITDA Margin % too high?
Jacobson Pharma's current EBITDA Margin % of 25.77% is 19% below median its 10-year median of 31.77. Over the past 10 years, this metric has ranged from a low of 25.06 to a high of 39.15. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Jacobson Pharma's value of 25.77% is 116.7% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #194 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #194 out of 959 companies for EBITDA Margin %. This places Jacobson Pharma in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.89. Jacobson Pharma's value of 25.77% is 116.7% above this benchmark. Historically, Jacobson Pharma's own EBITDA Margin % has ranged from 25.06 to 39.15 over the past decade. While the company's 10-year median is 31.77 vs. the industry median of 11.89, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current EBITDA Margin % of 25.77% is 116.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current EBITDA Margin % is 25.77%, which is 19% below median its own 10-year median of 31.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current EBITDA Margin % is 25.77%, which is 19% below median its 10-year median of 31.77 and 116.7% above the Drug Manufacturers industry median of 11.89. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current EBITDA Margin % is 25.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
EBITDA Margin %: 25.77% (19% below median its 10-year median of 31.77)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 116.7% above the Drug Manufacturers median (#194 of 959)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
